<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681872</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2019/55</org_study_id>
    <nct_id>NCT04681872</nct_id>
  </id_info>
  <brief_title>Marshall Ethanolization, Pulmonary Vein Isolation and Line Completion for Ablation of Persistent Atrial Fibrillation</brief_title>
  <acronym>MARSHALL-PLAN</acronym>
  <official_title>Marshall Ethanolization, Pulmonary Vein Isolation and Line Completion for Ablation of Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In ablation strategy for persistent Atrial Fibrillation (PsAF), ablation limited to Pulmonary&#xD;
      Vein (PV) isolation is the most straightforward approach but the result give only 50% of&#xD;
      arrhythmia free follow-up. Substrate modification strategies have failed to demonstrate their&#xD;
      superiority with variable reported success rate. The Marshall network is a highly&#xD;
      arrhythmogenic structure that has not been incorporated in current ablation strategies. The&#xD;
      investigators sought to investigate a new ablation strategy that target systematically the&#xD;
      vein of Marshall by ethanol infusion. This step is integrated in a new ablation strategy&#xD;
      consisting in a global anatomical substrate based ablation including PV isolation and left&#xD;
      atrial linear ablation (Marshall-Plan).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) characterized by a fast and anarchic electrical activation of the&#xD;
      atria, results in uncoordinated and inefficient atrial contractions that increases the risks&#xD;
      of heart failure and strokes. Besides being a major source of morbidity and mortality, AF is&#xD;
      one of the most common heart condition and its prevalence increases with age. Radiofrequency&#xD;
      catheter ablation of AF has become one of the treatment of choice in AF resistant to&#xD;
      conventional antiarrhythmic drugs. For paroxysmal AF, the ablation strategy is clear and&#xD;
      consists in complete pulmonary veins isolation (PVI). However, if this strategy works well in&#xD;
      paroxysmal AF, the recurrences rate remains high in persistent AF. Beyond PVI, the ablation&#xD;
      strategy that has prevailed over the past two decades remains controversial: the left atrium&#xD;
      partition using linear lesions (&quot;cox-maze&quot; strategy); the mapping of the left atrium in AF to&#xD;
      identify and localize the arrhythmia sources. Both methods have, besides favoring atrial&#xD;
      flutters, failed to demonstrated superiority compared to PVI alone (as showed by the clinical&#xD;
      trial STAR AF 2). The investigators aims to test a new method of ablation for patients&#xD;
      suffering from persistent AF in order to decrease post ablation recurrence. They propose a&#xD;
      strategy targeting the native structures facilitating reentries including the ligament of&#xD;
      Marshall (LOM), an embryological remnant. Indeed, two studies have demonstrated that LOM&#xD;
      could be the source of focal activities, the substrate of reentries and a strong&#xD;
      parasympathetic modulator. For these reasons, LOM may represent a major target in AF&#xD;
      treatment besides PV isolation. To date, ablation techniques do not ensure the complete&#xD;
      destruction of the Marshall's musculature and parasympathetic ganglia that surround it,&#xD;
      largely isolated by a sheath of adipose tissue. To overcome this technical limitation, LOM&#xD;
      elimination can be achieved by alcohol injection into the vein of Marshall. This innovative&#xD;
      approach will then consist in 3 consecutive steps: 1) the destruction of Marshall bundles by&#xD;
      ethanol infusion followed by the ablation of the distal and proximal muscular ramification&#xD;
      (coronary sinus and ridge); 2) the standard PV isolation; 3) the linear lesions: the mitral,&#xD;
      the roof and of the cavo-tricuspid isthmus, main causes of recurrence in atrial flutter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">September 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The Marshall Plan is a prospective randomized, parallel-group, multicenter clinical trial of superiority</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of AF or Atrial Tachycardia (AT) greater than 30 seconds with or without antiarrhythmic medications after a single ablation procedure</measure>
    <time_frame>2 years</time_frame>
    <description>Recurrence rate (percentage) of AF or AT &gt; 30 seconds after the blanking period of 3-months post ablation, at 2 years with or without antiarrhythmic medications after a single ablation procedure. Recurrences will be identified through transtelephonic electrocardiogram (ECG) monitor with weekly transmitted ECG and at any time in case of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of AF or AT greater than 30 seconds after multiple ablation procedures</measure>
    <time_frame>2 years</time_frame>
    <description>Recurrence rate (percentage) of AF or AT &gt; 30 seconds after the blanking period of 3-months post procedure, at 2 years after multiple ablation procedures. It will be identified through transtelephonic ECG monitor with weekly transmitted ECG and at any time in case of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of AF or AT greater than 30 seconds after a single ablation procedure (1)</measure>
    <time_frame>2 years</time_frame>
    <description>Recurrence rate (percentage) of AF or AT &gt; 30 seconds after the blanking period of 3-months post procedure, at 2 years, will be identified through transtelephonic ECG monitor with weekly transmitted ECG and at any time in case of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of AF greater than 30 seconds after a single ablation procedure (2)</measure>
    <time_frame>2 years</time_frame>
    <description>Recurrence rate (percentage) of AF &gt; 30 seconds after the blanking period of 3-months post procedure, at 2 years after a single ablation procedure. It will be identified through transtelephonic ECG monitor with weekly transmitted ECG and at any time in case of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of AF greater than 30 seconds after multiple ablation procedure.</measure>
    <time_frame>2 years</time_frame>
    <description>Recurrence rate (percentage) of AF &gt; 30 seconds after the blanking period of 3-months post procedure, at 2 years after a multiple ablation procedure. It will be identified through transtelephonic ECG monitor with weekly transmitted ECG and at any time in case of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of AF or AT greater than 30 seconds without antiarrhythmic medications after a single ablation procedure.</measure>
    <time_frame>2 years</time_frame>
    <description>Recurrence rate (percentage) of AF or AT &gt; 30 seconds after the blanking period of 3-months post procedure at 2-years without antiarrhythmic medications after a single ablation procedure. It will be identified through transtelephonic ECG monitor with weekly transmitted ECG and at any time in case of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of AF or AT greater than 30 seconds without antiarrhythmic medications after multiple ablation procedure.</measure>
    <time_frame>2 years</time_frame>
    <description>Recurrence rate (percentage) of AF or AT &gt; 30 seconds after the blanking period of 3-months post procedure at 2-years without antiarrhythmic medications after multiple ablation procedure. It will be identified through transtelephonic ECG monitor with weekly transmitted ECG and at any time in case of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients under antiarrhythmic medications</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with repeated procedures</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Percentage of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of periprocedural complications</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of periprocedural complications : transient ischemic attack or stroke, cardiac tamponade, atrioesophageal fistula, pericarditis, complications at access site (hematoma, arteriovenous fistula, pseudoaneurysm)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">262</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Marshall Plan arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo (1) the destruction of Marshall bundles by ethanol infusion followed by ablation of the distal coronary sinus bundles, the ridge and the saddle; (2) the standard pulmonary veins sleeves isolation; (3) and finally the ablation of the mitral, the roof, and the cavo-tricuspid isthmus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary vein isolation arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Destruction of Marshall bundles</intervention_name>
    <description>Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.</description>
    <arm_group_label>Marshall Plan arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary veins isolation</intervention_name>
    <description>Achievement of a wide disconnection of the right and left pulmonary veins.</description>
    <arm_group_label>Marshall Plan arm</arm_group_label>
    <arm_group_label>Pulmonary vein isolation arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Linear ablation in the left and right atria</intervention_name>
    <description>Ablation of the mitral, the roof, and the cavo-tricuspid isthmus</description>
    <arm_group_label>Marshall Plan arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years of both genders&#xD;
&#xD;
          -  Suitable candidate for catheter and ablation of atrial fibrillation defined as:&#xD;
             history of symptomatic persistent atrial fibrillation in the past year documented by&#xD;
             ECG,&#xD;
&#xD;
          -  Patient affiliated or beneficiary of social security scheme,&#xD;
&#xD;
          -  Free, informed and written consent signed by the participant and the principal&#xD;
             investigator (at least at the inclusion date and before all exams required for the&#xD;
             clinical research),&#xD;
&#xD;
          -  Effective contraception for women of childbearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior left atrial heart ablation procedure,&#xD;
&#xD;
          -  Documented left atrial thrombus or another abnormality which precludes catheter&#xD;
             introduction,&#xD;
&#xD;
          -  Contraindication to anticoagulation therapy (heparin, warfarin, or novel oral&#xD;
             anticoagulant (NOAC)),&#xD;
&#xD;
          -  Contraindication to iodinated contrast products (history of major immediate reaction,&#xD;
             thyrotoxicosis),&#xD;
&#xD;
          -  Ethanol hypersensitivity,&#xD;
&#xD;
          -  Unstable angina or ongoing myocardial ischemia,&#xD;
&#xD;
          -  Myocardial infarction within 3 months prior to inclusion,&#xD;
&#xD;
          -  Congenital heart disease, where the underlying abnormality increases the ablation&#xD;
             risk,&#xD;
&#xD;
          -  Severe bleeding, clotting or thrombotic disorder,&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy defined by a left ventricular septum thickness &gt; 1.5 cm,&#xD;
&#xD;
          -  Pregnant, parturient or nursing women,&#xD;
&#xD;
          -  Person unable to give informed consent,&#xD;
&#xD;
          -  Patient detained by judicial or administrative order, patient under legal protection&#xD;
             (guardianship, curators, safeguarding justice).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas DERVAL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine BENARD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas DERVAL, MD</last_name>
    <phone>(0)5 57 65 64 71</phone>
    <phone_ext>+33</phone_ext>
    <email>nicolas.derval@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Timothe LOOCK</last_name>
    <phone>(0)5 57 62 31 19</phone>
    <phone_ext>+33</phone_ext>
    <email>timothe.loock@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Sint Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sébastien KNECHT, MD PhD</last_name>
      <phone>495 848156</phone>
      <phone_ext>+32</phone_ext>
      <email>Sebastien.Knecht@azsintjan.be</email>
    </contact>
    <investigator>
      <last_name>Sébastien KNECHT, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Augustin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33074</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud DENIS, MD</last_name>
      <phone>(0)5 56 72 72 61</phone>
      <phone_ext>+33</phone_ext>
      <email>arnaud.denis@lilo.org</email>
    </contact>
    <investigator>
      <last_name>Arnaud DENIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ambroise Paré Hospital</name>
      <address>
        <city>Neuilly-sur-Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Les Franciscaines Hospital</name>
      <address>
        <city>Nîmes</city>
        <zip>30032</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agustin BORTONE, MD</last_name>
      <phone>(0)8 26 30 50 00</phone>
      <phone_ext>+33</phone_ext>
      <email>agubene@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Agustin BORTONE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Cardiologique du Nord</name>
      <address>
        <city>Saint-Denis</city>
        <zip>93200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine LEPILLIER, MD</last_name>
      <phone>(0)1 49 33 41 41</phone>
      <phone_ext>+33</phone_ext>
      <email>a.lepillier@ccn.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine LEPILLIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toulouse University Hospirtal</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe MAURY, MD</last_name>
      <phone>(0)5 61 32 30 54</phone>
      <phone_ext>+33</phone_ext>
      <email>maury.p@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe MAURY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Persistent atrial fibrillation</keyword>
  <keyword>Pulmonary vein isolation</keyword>
  <keyword>Catheter ablation</keyword>
  <keyword>Ethanolization</keyword>
  <keyword>Ligament of Marshall</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

